Amit M Algotar, MD, PhD, MPH

algotar@arizona.edu

Links

Department Profile

Physician-scientist with clinical practice focusing on cancer survivorship, obesity medicine and primary care. My research training is in clinical epidemiology and cancer biology that allows me to conduct patient centered clinical research.

Cancer Focus

Cancer survivorship, treating late and long-term effects of malignancy and its treatment, using lifestyle modalities to address cancer survivorship needs such as metabolic abnormality, fatigue and sarcopenic obesity.

Research Program Role

Cancer Prevention and Control Program

Display Name
Amit M Algotar, MD, PhD, MPH

Publications

Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.

Sun BL, Sun X, Casanova N, Garcia AN, Oita R, Algotar AM, Camp SM, Hernon VR, Gregory T, Cress AE, et al. 2020. Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target. EBioMedicine. 61:103059. doi:10.1016/j.ebiom.2020.103059.

EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN.

Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP. 2015. EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. J Frailty Aging. 4:107–10. doi:10.14283/jfa.2015.48.

Chronic use of NSAIDs and/or statins does not affect PSA or PSA velocity in men at high risk for prostate cancer.

Algotar AM, Behnejad R, Stratton MS, Stratton SP. 2014. Chronic use of NSAIDs and/or statins does not affect PSA or PSA velocity in men at high risk for prostate cancer. Cancer Epidemiol Biomarkers Prev. 23:2196–8. doi:10.1158/1055-9965.EPI-14-0605.

ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG, Yun S, Riley J, Nagy D, Dittamore R, et al. 2013. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate. 73:1233–40. doi:10.1002/pros.22675.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, et al. 2013. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 73:328–35. doi:10.1002/pros.22573.